Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 12/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 12/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.36 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13031306 | 0.86 | GRIN1 (0.46) | CXCR3GRIN1GRIN2BSMN1; SMN2 | |
| SCHEMBL3578439 | 0.85 | CXCR3 (0.40) | CXCR3KCNH2GRIN1GRIN2BSMN1; SMN2 | |
| SCHEMBL13031416 | 0.84 | CXCR3 (0.41) | CXCR3MAPT | |
| SCHEMBL4315545 | 0.83 | CXCR3 (0.42) | CXCR3KCNH2GRIN1GRIN2BSMN1; SMN2 | |
| SCHEMBL13031408 | 0.83 | LMNA (0.41) | CXCR3KCNH2GRIN2BSMN1; SMN2 | |
| SCHEMBL13031485 | 0.82 | LMNA (0.38) | MAPT | |
| SCHEMBL13031195 | 0.81 | PTGS2 (0.36) | GRIN1GRIN2BSMN1; SMN2 | |
| SCHEMBL13031454 | 0.81 | PTGS2 (0.35) | KCNH2GRIN1GRIN2BMAPT | |
| SCHEMBL13031140 | 0.81 | PTGS2 (0.36) | KCNH2GRIN1GRIN2B | |
| SCHEMBL13031159 | 0.80 | GRIN2B (0.35) | GRIN1GRIN2BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | CXCR3 1/4885KCNH2 2030/4885GRIN1 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.